In order to validate Aurora kinases as therapeutic targets for KRAS-induced lung cancer, it is important to show that inhibiting these kinases preferentially targets lung cancer cells expressing oncogenic KRAS. The gene discussed is KRAS; the disease is lung carcinoma.